Friday, 24 May 2024

WuXi STA opens new large-scale oligonucleotide and peptide manufacturing facility

07 July 2022 | News

Site enhances new modality CRDMO platform capacity for customers

Image credit: prnewswire

Image credit: prnewswire

WuXi STA, a subsidiary of China-based WuXi AppTec, has announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus.  

With the opening of the new 30,570 sq.ft. oligonucleotide plant, WuXi STA extends its leadership in oligonucleotide development and manufacturing worldwide, with four large-scale oligonucleotide production lines and more than 20 small- to mid-scale production lines that increase the overall manufacturing capacity of a single synthesis run from 1.9 mol to 6.0 mol.

The new 22,260 sq.ft. peptide plant features three new production lines with reactors that can accommodate up to 1,000 L, increasing WuXi STA's overall Solid Phase Peptide Synthesis (SPPS) total reactor volume to 6,490 L.

The new facility is an essential part of WuXi STA's comprehensive end-to-end Contract Research, Development, and Manufacturing Organization (CRDMO) platform for new modalities. The platform supports oligonucleotides and peptides, including novel monomers and linkers, and complex conjugates, from early discovery to development and commercial production at any scale. With this enhanced manufacturing capacity and over 850 dedicated scientists, WuXi STA's new modality CRDMO platform can better enable global partners as their projects progress to late and commercial stages.

WuXi STA has a global network of multiple R&D and manufacturing sites across AsiaNorth America and Europe, including a new pharmaceutical manufacturing campus in Middletown, Delaware that is scheduled to open in 2024.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account